The Effects of STW 5-II on Duodenal Mucosa and Symptoms in Functional Dyspepsia

Inclusion Criteria: * Patients ≥18 years newly to be treated with an FD/PDS diagnosis (Rome IV clinical criteria). * Newly to be treated patients are defined as patients currently not on any ongoing treatment for FD (including OTC medication) for the last 2 weeks. Medications such as PPI or others that may affect GI function and symptom should be stopped prior the trial (min 4 weeks). See list of forbidden medication. * Male or female using contraception or postmenopausal * Witnessed written informed consent * Capable to understand and comply with the study requirements Exclusion Criteria: Inclusion criteria: * Patients ≥18 years newly to be treated with an FD/PDS diagnosis (Rome IV clinical criteria). * Newly to be treated patients are defined as patients currently not on any ongoing treatment for FD (including OTC medication) for the last 2 weeks. Medications such as PPI or others that may affect GI function and symptom should be stopped prior the trial (min 4 weeks). See list of forbidden medication. * Male or female using contraception or postmenopausal * Witnessed written informed consent * Capable to understand and comply with the study requirements Exclusion criteria: * Major active somatic or psychiatric condition that may explain dyspeptic symptoms (stable dose of single antidepressant allowed for psychiatric indication, no limitation for other indications) Predominant symptoms of gastro-esophageal reflux disease (GERD) or irritable bowel syndrome (IBS) * Chron…